{"id":"https://openalex.org/W3135453045","doi":"https://doi.org/10.1016/j.clinthera.2021.01.027","title":"Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial","display_name":"Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial","publication_year":2021,"publication_date":"2021-03-06","ids":{"openalex":"https://openalex.org/W3135453045","doi":"https://doi.org/10.1016/j.clinthera.2021.01.027","mag":"3135453045","pmid":"https://pubmed.ncbi.nlm.nih.gov/33750646"},"language":"en","primary_location":{"id":"doi:10.1016/j.clinthera.2021.01.027","doi":"https://doi.org/10.1016/j.clinthera.2021.01.027","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2021.01.027","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.clinthera.2021.01.027","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034593787","display_name":"Azmi F. Nasser","orcid":"https://orcid.org/0000-0003-0514-8410","observed_orcids":["https://orcid.org/0000-0003-0514-8410","https://orcid.org/0000-0002-3324-0161"]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Azmi Nasser","raw_affiliation_strings":["Supernus Pharmaceuticals, Inc., Rockville, MD, USA. Electronic address: anasser@supernus.com","Supernus Pharmaceuticals, Inc., Rockville, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA. Electronic address: anasser@supernus.com","institution_ids":["https://openalex.org/I4210138615"]},{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065963598","display_name":"Tesfaye Liranso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tesfaye Liranso","raw_affiliation_strings":["Supernus Pharmaceuticals, Inc., Rockville, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009610620","display_name":"Toyin Adewole","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Toyin Adewole","raw_affiliation_strings":["Supernus Pharmaceuticals, Inc., Rockville, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029826453","display_name":"Nicholas Fry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas Fry","raw_affiliation_strings":["Supernus Pharmaceuticals, Inc., Rockville, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069076161","display_name":"Joseph T. Hull","orcid":"https://orcid.org/0000-0003-1409-3538","observed_orcids":["https://orcid.org/0000-0003-1409-3538"]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph T. Hull","raw_affiliation_strings":["Supernus Pharmaceuticals, Inc., Rockville, MD, USA"],"raw_orcid":"https://orcid.org/0000-0003-1409-3538","affiliations":[{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078800484","display_name":"Fatima A. Chowdhry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fatima Chowdhry","raw_affiliation_strings":["Supernus Pharmaceuticals, Inc., Rockville, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030533076","display_name":"Gregory D. Busse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory D. Busse","raw_affiliation_strings":["Supernus Pharmaceuticals, Inc., Rockville, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112837345","display_name":"Zare Melyan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zare Melyan","raw_affiliation_strings":["Supernus Pharmaceuticals, Inc., Rockville, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102774504","display_name":"Andrew J. Cutler","orcid":"https://orcid.org/0000-0001-5800-0378","observed_orcids":["https://orcid.org/0000-0001-5800-0378"]},"institutions":[{"id":"https://openalex.org/I20388574","display_name":"SUNY Upstate Medical University","ror":"https://ror.org/040kfrw16","country_code":"US","type":"education","lineage":["https://openalex.org/I20388574"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew J. Cutler","raw_affiliation_strings":["SUNY Upstate Medical University, and Neuroscience Education Institute, Lakewood Ranch, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SUNY Upstate Medical University, and Neuroscience Education Institute, Lakewood Ranch, FL, USA","institution_ids":["https://openalex.org/I20388574"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042787535","display_name":"Robert L. Findling","orcid":"https://orcid.org/0000-0002-7654-5782","observed_orcids":["https://orcid.org/0000-0002-7654-5782"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert L. Findling","raw_affiliation_strings":["School of Medicine, Virginia Commonwealth University, Richmond, VA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medicine, Virginia Commonwealth University, Richmond, VA, USA","institution_ids":["https://openalex.org/I184840846"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035263710","display_name":"Stefan Schwabe","orcid":"https://orcid.org/0000-0002-1426-2584","observed_orcids":["https://orcid.org/0000-0002-1426-2584"]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefan Schwabe","raw_affiliation_strings":["Supernus Pharmaceuticals, Inc., Rockville, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Supernus Pharmaceuticals, Inc., Rockville, MD, USA","institution_ids":["https://openalex.org/I4210138615"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5034593787"],"corresponding_institution_ids":["https://openalex.org/I4210138615"],"apc_list":{"value":3970,"currency":"USD","value_usd":3970},"apc_paid":{"value":3970,"currency":"USD","value_usd":3970},"fwci":7.3178,"has_fulltext":false,"cited_by_count":56,"citation_normalized_percentile":{"value":0.98280251,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":99},"biblio":{"volume":"43","issue":"4","first_page":"684","last_page":"700"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/viloxazine","display_name":"viloxazine","score":0.8519999980926514},{"id":"https://openalex.org/keywords/extended-release-formulation","display_name":"sustained-release formulation","score":0.7149999737739563},{"id":"https://openalex.org/keywords/attention-deficit-hyperactivity-disorder","display_name":"attention deficit hyperactivity disorder","score":0.9629999995231628},{"id":"https://openalex.org/keywords/children-with-adhd","display_name":"children with ADHD","score":0.6549999713897705},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.9120000004768372},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.6430000066757202},{"id":"https://openalex.org/keywords/conners-3","display_name":"Conners 3","score":0.6240000128746033},{"id":"https://openalex.org/keywords/weiss-functional-impairment-rating-scale","display_name":"Weiss Functional Impairment Rating Scale","score":0.9200000166893005},{"id":"https://openalex.org/keywords/functional-disability","display_name":"functional disability","score":0.7860000133514404},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.8880000114440918},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7559999823570251},{"id":"https://openalex.org/keywords/stimulant-medication","display_name":"stimulant medication","score":0.4269999861717224},{"id":"https://openalex.org/keywords/school-aged-children","display_name":"school-aged children","score":0.6230000257492065},{"id":"https://openalex.org/keywords/dose-titration","display_name":"dose titration","score":0.48500001430511475}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9427748918533325},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5881736874580383},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.41994157433509827},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.41681843996047974},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.32858625054359436},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.188848614692688},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012574","descriptor_name":"Schools","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.clinthera.2021.01.027","doi":"https://doi.org/10.1016/j.clinthera.2021.01.027","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2021.01.027","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},{"id":"pmid:33750646","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33750646","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1016/j.clinthera.2021.01.027","doi":"https://doi.org/10.1016/j.clinthera.2021.01.027","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2021.01.027","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320315664","display_name":"Supernus Pharmaceuticals","ror":"https://ror.org/03sd6kg46"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":56,"referenced_works":["https://openalex.org/W611030976","https://openalex.org/W1128065552","https://openalex.org/W1849348377","https://openalex.org/W1970031540","https://openalex.org/W1976641170","https://openalex.org/W1998954528","https://openalex.org/W2008749138","https://openalex.org/W2010073589","https://openalex.org/W2016652500","https://openalex.org/W2023351650","https://openalex.org/W2050973084","https://openalex.org/W2058562698","https://openalex.org/W2063060447","https://openalex.org/W2081432348","https://openalex.org/W2082643307","https://openalex.org/W2110145837","https://openalex.org/W2114290463","https://openalex.org/W2121519528","https://openalex.org/W2127950365","https://openalex.org/W2129129238","https://openalex.org/W2130386846","https://openalex.org/W2136389780","https://openalex.org/W2138606137","https://openalex.org/W2148083007","https://openalex.org/W2155877415","https://openalex.org/W2157382328","https://openalex.org/W2159011576","https://openalex.org/W2162012775","https://openalex.org/W2164896423","https://openalex.org/W2182459892","https://openalex.org/W2186549343","https://openalex.org/W2210949977","https://openalex.org/W2237269582","https://openalex.org/W2259851685","https://openalex.org/W2269759715","https://openalex.org/W2489026659","https://openalex.org/W2523347043","https://openalex.org/W2550664767","https://openalex.org/W2565331137","https://openalex.org/W2565831906","https://openalex.org/W2590605442","https://openalex.org/W2590743000","https://openalex.org/W2605673357","https://openalex.org/W2724395843","https://openalex.org/W2800292090","https://openalex.org/W2886298463","https://openalex.org/W2922182075","https://openalex.org/W2932351473","https://openalex.org/W2933452394","https://openalex.org/W3045331755","https://openalex.org/W3080466884","https://openalex.org/W3084409057","https://openalex.org/W4213383170","https://openalex.org/W4322706538","https://openalex.org/W6686128590","https://openalex.org/W7073737076"],"related_works":["https://openalex.org/W3045331755","https://openalex.org/W3020454955","https://openalex.org/W2933452394","https://openalex.org/W3170851891","https://openalex.org/W3019618496","https://openalex.org/W4386797299","https://openalex.org/W3018486295","https://openalex.org/W7093077183","https://openalex.org/W4213328100","https://openalex.org/W2920824736"],"abstract_inverted_index":{"PURPOSE:":[0],"SPN-812":[1,28,50,53,169,208,235,242],"(viloxazine":[2],"extended-release)":[3],"is":[4],"under":[5],"investigation":[6],"for":[7,60],"the":[8,23,73,137,152,187,216],"treatment":[9,236],"of":[10,27,39,87,129,227],"attention-deficit/hyperactivity":[11],"disorder":[12],"(ADHD)":[13],"in":[14,35,78,102,114,136,154,189,220,233,253,256],"children":[15,36,258],"and":[16,25,30,112,158,167,176,183,244,259],"adolescents.":[17],"This":[18],"Phase":[19],"III":[20],"study":[21,88],"evaluated":[22],"efficacy":[24,70],"tolerability":[26],"200":[29,51,243],"400":[31,54,245],"mg":[32,246],"once":[33,58,247],"daily":[34,59,248],"6-11":[37],"years":[38],"age":[40,145],"with":[41,134,164,197,251],"ADHD.":[42],"METHODS:":[43],"Patients":[44],"were":[45,132,161],"randomly":[46],"assigned":[47],"to":[48,210,230],"receive":[49],"mg,":[52,55],"or":[56],"placebo,":[57],"8":[61],"weeks":[62,65],"(including":[63],"\u22643":[64],"titration":[66],"period).":[67],"The":[68,225],"primary":[69],"endpoint":[71],"was":[72,194,218,239,249,260],"change":[74],"from":[75],"baseline":[76],"(CFB)":[77],"ADHD":[79,254],"Rating":[80,118],"Scale":[81],"(RS)-5":[82],"Total":[83,121,156,222],"score":[84,98,123,157,160],"at":[85,99,110,124],"end":[86],"(EOS).":[89],"Key":[90],"secondary":[91],"endpoints":[92],"included":[93],"Clinical":[94],"Global":[95],"Impression-Improvement":[96],"(CGI-I)":[97],"EOS,":[100,111,151,186],"CFB":[101,113,188],"Conners":[103,190],"3-Parent":[104],"Short":[105],"Form":[106],"(PS)":[107],"composite":[108,192],"T-score":[109,193],"Weiss":[115],"Functional":[116],"Impairment":[117],"Scale-Parent":[119],"(WFIRS-P)":[120],"average":[122,223],"EOS.":[125],"FINDINGS:":[126],"A":[127],"total":[128],"313":[130],"patients":[131],"enrolled,":[133],"301":[135],"intent-to-treat":[138],"population":[139],"(194":[140],"boys,":[141],"107":[142],"girls;":[143],"mean":[144],"[SD],":[146],"8.4":[147],"[1.7]":[148],"years).":[149],"At":[150,185],"CFBs":[153],"ADHD-RS-5":[155],"CGI-I":[159],"significantly":[162,195],"improved":[163,196],"both":[165,234],"200-":[166,198],"400-mg/d":[168,204],"versus":[170],"placebo":[171],"(ADHD-RS-5,":[172],"P":[173,180],"=":[174,181,200,206],"0.0038":[175],"0.0063,":[177],"respectively;":[178],"CGI-I,":[179],"0.0028":[182],"0.0099).":[184],"3-PS":[191],"(P":[199,205],"0.0064),":[201],"but":[202],"not":[203],"0.0917),":[207],"compared":[209],"placebo.":[211],"No":[212],"significant":[213],"difference":[214],"between":[215],"groups":[217,237],"found":[219],"WFIRS-P":[221],"score.":[224],"rate":[226],"discontinuations":[228],"due":[229],"adverse":[231],"events":[232],"combined":[238],"<5%.":[240],"IMPLICATIONS:":[241],"associated":[250],"improvements":[252],"symptoms":[255],"school-aged":[257],"generally":[261],"well":[262],"tolerated.":[263],"ClinicalTrials.gov":[264],"identifier:":[265],"NCT03247543.":[266]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":14},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":13},{"year":2021,"cited_by_count":13}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2021-03-15T00:00:00"}